Exact Sciences (NASDAQ: EXAS) reported Q1 EPS of ($0.40), $0.01 better than the analyst estimate of ($0.41). Revenue for the quarter came in at $4.3 million versus the consensus estimate of $4.11 million.

11,000 Cologuard tests were completed and the number of ordering physicians more than doubled, increasing from 4,100 at the end of 2014 to 8,300 in the first quarter of 2015.

“We are pleased with the strong launch trajectory of Cologuard,” said Kevin Conroy, Exact Sciences’ chairman and CEO. “Demand among patients and physicians and acceptance among commercial insurers is accelerating.”

For earnings history and earnings-related data on Exact Sciences (EXAS) click here.